人呼吸道合胞病毒疫苗的临床研究进展  

Clinical research progress of human respiratory syncytial virus vaccine

作　　者：姜明月 徐韵韶 许松涛[2] 冯录召 Jiang Mingyue;Xu Yunshao;Xu Songtao;Feng Luzhao(School of Population Medicine and Public Health,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing 102206,Chin)

机构地区：[1]中国医学科学院北京协和医学院群医学及公共卫生学院,北京100730 [2]中国疾病预防控制中心病毒病预防控制所国家卫生健康委员会医学病毒和病毒病重点实验室,北京102206

出　　处：《中华预防医学杂志》2023年第1期70-77,共8页Chinese Journal of Preventive Medicine

摘　　要：人呼吸道合胞病毒(HRSV)是引起婴幼儿和老年人严重急性下呼吸道感染的主要病原体之一,其发病率和病死率在全球范围内均较高。疫苗是预防HRSV感染、传播、重症的重要手段之一,但全球尚未有正式获批的HRSV预防性疫苗。本文对当前HRSV疫苗的研发进展进行梳理和分析,概述不同类型HRSV预防性疫苗的设计路线并讨论在疫苗研发中面临的困难挑战,以期为我国HRSV疫苗的研发和临床试验的开展提供参考。Human respiratory syncytial virus(HRSV)is one of the main pathogen causing severe acute lower respiratory tract infections in infants and the elderly,with high incidence rate and mortality worldwide.Vaccine is one of the important measure to prevent infection,transmission and severe disease of HRSV,but currently there is no officially approved preventive vaccine for prevention of HRSV in the world.This paper reviews and analyzes the current research and development progress of HRSV vaccine,summarizes the design routes of different types of HRSV preventive vaccines,and discusses the difficulties and challenges in vaccine research and development,in order to provide reference for the research and development of HRSV vaccine and the development of clinical trials.

关 键 词：呼吸道合胞体病毒 人 疫苗 研究进展 

分 类 号：R392[医药卫生—免疫学]